

Amendments to the Written Description

Please replace the paragraph on page 3, line 19, (paragraph [0017] of the instant published application) with the following amended paragraph:

--f) optionally, an ~~organic~~ inorganic base, Lewis base, or aliphatic amine;--

To correct typographical and nomenclature errors, please replace the paragraph on page 23, lines 7-19, (paragraph [0163] of the instant published application) with the following amended paragraph:

--(2.6) Sterically hindered amines, such as, for example bis-(2,2,6,6-tetramethylpiperidyl)-sebacate; bis-(1,2,2,6,6-pentamethylpiperidyl)-sebacate; ~~n-butyl-3,5-di-t-butyl-4-hydroxybenzyl malonic acid; bis-(1,2,2,6,6-pentamethylpiperidyl)ester~~ n-butyl-3,5-di-t-butyl-4-hydroxybenzyl malonic acid bis-(1,2,2,6,6-pentamethylpiperidyl)ester; condensation product of 1-hydroxyethyl-2,2,6,6-tetramethyl-4-hydroxy-piperidine and succinic acid; condensation product of N,N'-(2,2,6,6-tetramethylpiperidyl)-hexamethyldiamine and 4-t-octylamino-2,6-dichloro-1,3,5-s-triazine; tris-(2,2,6,6-tetramethylpiperidyl)-nitrilotriacetate; tetrakis-(2,2,6,6-tetramethyl-4-piperidyl)-1,2,3,5-butane-tetracarboxylic acid; 1,1'-(1,2-ethanediyl)-bis-(3,3,5,5-tetramethylpiperazinone). Such amines include hydroxylamines derived from hindered amines, such as di-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)sebacate; 1-hydroxy-2,2,6,6-tetramethyl-4-benzoxypiperidine; 1-hydroxy-2,2,6,6-tetramethyl-4(3,5-di-t-butyl-4-hydroxyhydrocinnamoyloxy)piperidine; and N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-ε-caprolactam.--

Please replace the paragraph on page 27, line 16, (paragraph [0191] of the instant published application) with the following amended paragraph:

--f) optionally, an ~~organic~~ inorganic base, Lewis base, or aliphatic amine;--